However, given the evolving role to monitor mutant NPM1 levels to check response to initial chemotherapy (19), and given the usual 2 week turn-around time of NGS reporting, IHC staining at initial AML diagnosis could aid in the rapid identification of NPM1-mutated AML cases needing baseline RT-PCR. This evidence concerns the gene NPM1 and acute myeloid leukemia.